Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR84 | Q9NQS5 | 2/20 | 0.43 |
| ▸ | S1PR2 | O95136 | 1/20 | 0.43 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.43 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.43 |
| ▸ | CNR2 | P34972 | 6/20 | 0.41 |
| ▸ | PTGS2 | P35354 | 3/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | CA2 | P00918 | 2/20 | 0.39 |
| ▸ | CA1 | P00915 | 1/20 | 0.39 |
| ▸ | CA9 | Q16790 | 1/20 | 0.39 |
| ▸ | FUT7 | Q11130 | 1/20 | 0.38 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.36 |
| ▸ | SRC | P12931 | 2/20 | 0.35 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9446177 | 0.87 | CNR2 (0.35) | S1PR2S1PR1S1PR3CNR2 | |
| SCHEMBL23322413 | 0.83 | GPR84 (0.55) | GPR84S1PR2S1PR1S1PR3PTGS2 | |
| SCHEMBL9162575 | 0.82 | S1PR2 (0.36) | GPR84S1PR2S1PR1S1PR3CNR2 | |
| SCHEMBL23322335 | 0.81 | S1PR2 (0.55) | GPR84S1PR2S1PR1S1PR3PTGS2 | |
| SCHEMBL243317 | 0.79 | CYP2C19 (0.37) | CNR2CYP3A4 | |
| SCHEMBL9551526 | 0.78 | CYP2C19 (0.36) | CNR2CYP3A4 | |
| SCHEMBL5509286 | 0.78 | CNR2 (0.34) | CNR2CYP3A4TRPV1SRC | |
| SCHEMBL244699 | 0.75 | MAPT (0.37) | CNR2 | |
| SCHEMBL5529306 | 0.74 | MAPT (0.36) | CNR2 | |
| SCHEMBL5526466 | 0.74 | MAPT (0.36) | CNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1813680-B1 | COMPOSITIONS FOR LIPASE ACTIVITY DETERMINATION AND METHOD OF DETERMINING ACTIVITY | ASAHI KASEI PHARMA CORP (JP) | 2011-11-09 | — | — | EP | disclosed |
| US-7883862-B2 | comprising at least one diglyceride, a low concentration buffer, and a nonionic surfactant; for determining activity of pancreatic lipase or non-pancreatic lipases (such as hepatic lipase or lipoprotein lipase) in clinical laboratory tests | ASAHI KASEI PHARMA CORPORATION (JP) | 2011-02-08 | — | — | US | disclosed |
| US-20080038765-A1 | Composition for Lipase Activity Determination and Method of Determing Activity | ASAHI KASEI PHARMA CORPORATION (JP) | 2008-02-14 | — | — | US | disclosed |
| EP-1813680-A1 | COMPOSITIONS FOR LIPASE ACTIVITY DETERMINATION AND METHOD OF DETERMINING ACTIVITY | Asahi Kasei Pharma Corporation (JP) | 2007-08-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080038765-A1 | Composition for Lipase Activity Determination and Method of Determing Activity | LPL, GK, LIPG | GPR84 2869/4885S1PR2 2705/4885S1PR1 2647/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.